公开(公告)号：US20240245694A1

公开(公告)日：2024-07-25

申请号：US18483651

申请日：2023-10-10

Applicant: Novartis AG

Inventor： Vincent BORDAS ,  Markus FUREGATI ,  Jacques HAMON ,  Jürgen Hans-Hermann HINRICHS ,  Ziyue HONG ,  Fabio LIMA ,  Fatma LIMAM ,  Henrik MOEBITZ ,  Sandro NOCITO ,  Niko SCHMIEDEBERG ,  Joseph SCHOEPFER ,  Ross Sinclair STRANG ,  Frédéric ZECRI ,  Huangchao YU ,  Yong ZHANG ,  Xinkan YANG ,  Sisi ZHANG ,  Wei LI

IPC: A61K31/5377 ,  A61K31/519 ,  C07D487/14 ,  C07D519/00

CPC classification number: A61K31/5377 ,  A61K31/519 ,  C07D487/14 ,  C07D519/00

Abstract: The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I):




wherein R1, R2, R3, x, R4, R5, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.

公开(公告)号：US20240317721A1

公开(公告)日：2024-09-26

申请号：US18571588

申请日：2022-06-22

Applicant: NOVARTIS AG

Inventor： Claudio BOMIO-CONFAGLIA ,  Saskia Maria BRACHMANN ,  Simona COTESTA ,  Marc GERSPACHER ,  Catherine LEBLANC ,  Fabio LIMA ,  Edwige Liliane Jeanne LORTHIOIS ,  Rainer MACHAUER ,  Robert MAH ,  Sophie RACINE ,  Pascal RIGOLLIER ,  Stefan STUTZ ,  Andrea VAUPEL ,  Nicolas WARIN ,  Rainer WILCKEN ,  Frédéric ZECRI

IPC: C07D403/14 ,  A61K31/416 ,  A61K31/4162 ,  A61K31/437 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/499 ,  A61K31/4995 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/547 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61K31/675 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D491/048 ,  C07D491/107 ,  C07D495/10 ,  C07D498/04 ,  C07D498/08 ,  C07D498/10 ,  C07D513/08 ,  C07F9/6584

CPC classification number: C07D403/14 ,  A61K31/416 ,  A61K31/4162 ,  A61K31/437 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/499 ,  A61K31/4995 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/547 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61K31/675 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D491/048 ,  C07D491/107 ,  C07D495/10 ,  C07D498/04 ,  C07D498/08 ,  C07D498/10 ,  C07D513/08 ,  C07F9/6584

Abstract: The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, and the therapeutic uses of said compound. The present invention further provides a pharmaceutical composition comprising said compound.

公开(公告)号：US20250115572A1

公开(公告)日：2025-04-10

申请号：US18729949

申请日：2023-01-20

Applicant: Novartis AG

Inventor： Christopher M. ADAMS ,  Lara C. CZABANIUK ,  Stefanie FLOHR ,  François GESSIER ,  Michael Christoph HEDIGER ,  Konstanze HURTH ,  Nancy LABBE-GIGUERE ,  Fabio LIMA ,  Tajesh PATEL ,  Oliver SIMIC ,  Martin SENDZIK ,  Angela VITREY ,  Anna VULPETTI

IPC: C07D401/06 ,  A61K31/438 ,  A61K31/444 ,  C07D401/14 ,  C07D405/14

Abstract: Provided herein are compounds of formula (I) and pharmaceutical compositions thereof useful for treating diseases or disorders mediated by the complement factor B. (I).